KMT2D and diffuse large B-cell lymphoma: DLBCL-associated KMT2D mutations impair KMT2D enzymatic activity, leading to diminished global H3K4 methylation in GCB cells and DLBCL cells (47), and KMT2D could be a modulator of ICP blockade (30).